Background: The impact on health related quality of life (HRQoL) of rituximab maintenance (R-M) versus observation (OBS) after induction for treatment of follicular lymphoma (FL) is unclear.
Methods: We reviewed the charts of 137 patients (53% female, 87% White, age 61.0 ± 12.4 years) who received either R-M (n = 53) or OBS (n = 84) after chemotherapy induction for newly diagnosed FL at community oncology practices within the US. Patients (65% with advanced disease; 48% with a high FLIPI score [3–5]) had completed ≥1 Patient Care Monitor HRQoL survey in the period following front-line therapy, and were excluded if they had progressed during front-line therapy.
Results: Linear mixed models showed that postinduction, most symptoms were stable, with patients on R-M reporting HRQoL that was equal to that reported by OBS patients.
Conclusions: Among R-M patients, receipt of rituximab was associated with improved psychological symptoms.
BolandA.BagustA.HockenhullJ.DavisH.ChuP.DicksonR. (2009) Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma. Health Technol Assess13(Suppl. 2): 41–48.
2.
BuskeC.HosterE.DreylingM.HasfordJ.UnterhaltM.HiddemannW. (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood108: 1504–1508.
3.
CheungM.C.ImrieK.R.FriedlichJ.BucksteinR.LathiaN.MittmannN. (2009) The impact of follicular (FL) and other indolent non-Hodgkin's lymphomas (NHL) on work productivity-a preliminary analysis. Psychooncology18: 554–559.
4.
CnaanA.LairdN.M.SlasorP. (1997) Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med16: 2349–2380.
5.
CopayA.G.SubachB.R.GlassmanS.D.PollyD.W.JrSchulerT.C. (2007) Understanding the minimum clinically important difference: a review of concepts and methods. Spine J7: 541–546.
6.
DavisT.A.Grillo-LopezA.J.WhiteC.A.McLaughlinP.CzuczmanM.S.LinkB.K. (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol18: 3135–3143.
7.
DehejiaR.H.WahbaS. (1999) Causal effects in nonexperimental studies: reevaluating the evaluation of training programs. J Am Statist Assoc94: 1053–1062.
8.
FisherR.I.LeBlancM.PressO.W.MaloneyD.G.UngerJ.M.MillerT.P. (2005) New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol23: 8447–8452.
9.
ForstpointnerR.UnterhaltM.DreylingM.BockH.P.ReppR.WandtH. (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood108: 4003–4008.
10.
FortnerB.BaldwinS.SchwartzbergL.HoutsA.C. (2006) Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. J Pain Symptom Manage31: 207–214.
11.
FriedbergJ.W.TaylorM.D.CerhanJ.R.FlowersC.R.DillonH.FarberC.M. (2009) Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol27: 1202–1208.
12.
Ghielmini, M.E., Schmitz, S.H., Martinelli, G., Peccatori, F., Hess, U., Fey, M. et al. (2009) Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology, 29 May–2 June, Orlando, FL.
13.
GineE.Gutierrez-GarciaG.Lopez-GuillermoA. (2010) Current immunochemotherapy strategies in follicular lymphoma. Adv Therin press.
14.
HainsworthJ.D. (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial. Semin Oncol29(1 Suppl. 2): 25–29.
15.
HochsterH.WellerE.GascoyneR.D.HabermannT.M.GordonL.I.RyanT. (2009) Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol27: 1607–1614.
16.
HoutsA.C.LipinskiD.OlsenJ.P.BaldwinS.HasanM. (2009) Use of the patient care monitor to screen for depression in adult cancer patients interviewed with the structured clinical interview for DSM-IV.. Psychooncologyin press.
17.
JaeschkeR.SingerJ.GuyattG.H. (1989) Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials10: 407–415.
18.
KeatingG.M. (2010) Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs70: 1445–1476.
19.
LittellR.C.PendergastJ.NatarajanR. (2000) Modelling covariance structure in the analysis of repeated measures data. Stat Med19: 1793–1819.
20.
MaloneyD.G. (2008) What is the role of maintenance rituximab in follicular NHL?Oncology (Williston Park)22: 20–26. discussion 26, 29, 33–24.
21.
MarcusR.ImrieK.Solal-CelignyP.CatalanoJ.V.DmoszynskaA.RaposoJ.C. (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol26: 4579–4586.
PettengellR.DonattiC.HoskinP.PoyntonC.KettleP.J.HancockB. (2008) The impact of follicular lymphoma on health-related quality of life. Ann Oncol19: 570–576.
24.
RevickiD.HaysR.D.CellaD.SloanJ. (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol61: 102–109.
RosenbaumP.R.RubinD.B. (1984) Reducing bias in observational studies using subclassification on the propensity score. J Am Statist Assoc79: 516–524.
27.
SallesG.SeymourJ.F.OffnerF.Lopez-GuillermoA.BeladaD.XerriL. (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet377: 42–51.
28.
Solal-CelignyP.CahuX.CartronG. (2010) Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?Int J Hematol92: 246–254.
29.
StepanskiE.J.WalkerM.S.SchwartzbergL.S.BlakelyL.J.OngJ.C.HoutsA.C. (2009) The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with cancer. J Clin Sleep Med5: 132–136.
30.
TillyH.ZelenetzA. (2008) Treatment of follicular lymphoma: current status. Leuk Lymphoma49(Suppl. 1): 7–17.
31.
van OersM.H.Van GlabbekeM.GiurgeaL.KlasaR.MarcusR.E.WolfM. (2010) Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol28: 2853–2858.
32.
VidalL.Gafter-GviliA.LeiboviciL.DreylingM.GhielminiM.Hsu SchmitzS.F. (2009) Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst101: 248–255.
33.
WalkerM.S.SchwartzbergL.S.StepanskiE.J.FortnerB.V. (2009) A retrospective study of quality of life in a community sample of patients with early stage breast cancer. Breast Cancer Res Treat115: 415–422.
34.
WebsterK.CellaD. (1998) Quality of life in patients with low-grade non-Hodgkin's lymphoma. Oncology (Williston Park)12: 697–714. discussion 714, 717, 721.
35.
Witzens-HarigM.ReizM.HeissC.BennerA.HenselM.NebenK. (2009) Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial. Ann Hematol88: 51–57.
36.
WitzigT.E.VukovA.M.HabermannT.M.GeyerS.KurtinP.J.FriedenbergW.R. (2005) Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol23: 1103–1108.
